Abstract
While a great deal of information is available on the cellular and molecular biology of cartilage degradation, less is known about anabolism in normal cartilage and degenerating cartilage. A consistent amount of evidence is now available on the neo-synthesis of matrix molecules and enzymes in OA: the entire cell metabolism appears to be increased leading to the hypothesis that chondrocytes in OA are actually “activated”. This chapter will focus on anabolic events that are now known to occur in articular cartilage. We will begin to view articular cartilage as a complex three-dimensional tissue in which local events may be different. We will also be interested in viewing the development of degenerative arthritis as a continuum from functionally normal tissue to degeneration.
Keywords: Osteoarthritis, chondrocytes, anabolism, BMP-2, IL-1, neo-synthesis, cartilage, Type II collagen
Current Drug Targets
Title: Anabolic Factors in Degenerative Joint Disease
Volume: 8 Issue: 2
Author(s): L. J. Sandell
Affiliation:
Keywords: Osteoarthritis, chondrocytes, anabolism, BMP-2, IL-1, neo-synthesis, cartilage, Type II collagen
Abstract: While a great deal of information is available on the cellular and molecular biology of cartilage degradation, less is known about anabolism in normal cartilage and degenerating cartilage. A consistent amount of evidence is now available on the neo-synthesis of matrix molecules and enzymes in OA: the entire cell metabolism appears to be increased leading to the hypothesis that chondrocytes in OA are actually “activated”. This chapter will focus on anabolic events that are now known to occur in articular cartilage. We will begin to view articular cartilage as a complex three-dimensional tissue in which local events may be different. We will also be interested in viewing the development of degenerative arthritis as a continuum from functionally normal tissue to degeneration.
Export Options
About this article
Cite this article as:
Sandell J. L., Anabolic Factors in Degenerative Joint Disease, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940142
DOI https://dx.doi.org/10.2174/138945007779940142 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry The Biology and Medicinal Chemistry of Epothilones
Current Medicinal Chemistry - Anti-Cancer Agents Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Subject Index to Volume 4
Current Drug Targets Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Structural Insights into the Exchange Domain of Sec2p: Expression, Purification,Crystallization, and Preliminary X-Ray Diffraction Data Analysis
Protein & Peptide Letters Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine